Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | CCR2 | P41597 | 3/20 | 0.60 |
| ▸ | CCR1 | P32246 | 1/20 | 0.60 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.54 |
| ▸ | METAP2 | P50579 | 2/20 | 0.53 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.52 |
| ▸ | FLT4 | P35916 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114776 | 0.88 | SLC10A6 (0.62) | ALDH1A1KDM4EHPGDHSD17B10BDKRB1 | |
| SCHEMBL3416851 | 0.87 | KDM4E (0.60) | ALDH1A1KDM4EHPGDMEN1KMT2A | |
| SCHEMBL11010265 | 0.86 | CCR2 (0.61) | ALDH1A1KDM4ECCR2CCR1BDKRB1 | |
| SCHEMBL12200779 | 0.86 | CCR2 (0.73) | ALDH1A1KDM4EHSD17B10CCR2CCR1 | |
| SCHEMBL15821566 | 0.85 | LMNA (0.67) | ALDH1A1KDM4EHPGDHSD17B10KMT2A | |
| SCHEMBL29531113 | 0.85 | IKBKB (0.60) | ALDH1A1KDM4EHPGDBDKRB1MEN1 | |
| SCHEMBL31709056 | 0.82 | CCR2 (0.68) | ALDH1A1KDM4ECCR2CCR1MEN1 | |
| SCHEMBL2534648 | 0.82 | BDKRB1 (0.73) | ALDH1A1KDM4EHPGDHSD17B10CCR2 | |
| SCHEMBL1037932 | 0.81 | HSD17B2 (0.66) | ALDH1A1KDM4EHPGD | |
| SCHEMBL7208749 | 0.81 | PTGES2 (0.63) | ALDH1A1KDM4EHPGDCCR2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582673-B2 | Benzo[b]thiophene-2-sulfonic acid [2-(2-chloro-5-trifluoromethylbenzenesulfonylamino)phenyl] amide; agonists of GalR1; useful in treating neuropathic pain or cancer | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-09-01 | — | — | US | claimed |
| EP-1809619-A1 | BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2007-07-25 | — | — | EP | claimed |
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | VTVX HOLDINGS II LLC | 2006-05-18 | — | — | US | claimed |
| WO-2006047302-A1 | BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2006-05-04 | — | — | WO | claimed |
| EP-1187531-A4 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-05-28 | — | — | EP | claimed |
| EP-1187531-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-03-20 | — | — | EP | claimed |
| WO-2000078145-A1 | MACROPHAGE SCAVENGER RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-12-28 | — | — | WO | claimed |
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | MJALLI ADNAN M M | 2009-10-01 | — | — | US | disclosed |
| US-7582673-B2 | Benzo[b]thiophene-2-sulfonic acid [2-(2-chloro-5-trifluoromethylbenzenesulfonylamino)phenyl] amide; agonists of GalR1; useful in treating neuropathic pain or cancer | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1809619-A1 | BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | VTVX HOLDINGS II LLC | 2006-05-18 | — | — | US | disclosed |
| WO-2006047302-A1 | BISSULFONAMIDE COMPOUNDS AS AGONISTS OF GALR1, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106089-A1 | Bissulfonamide compounds as agonists of GalR1, compositions, and methods of use | GALR1, GALR3, GALR2 | ALDH1A1 4001/4885KDM4E 2832/4885HPGD 3671/4885 |
| US-20090247536-A1 | Bissulfonamide Compounds As Agonists Of GalR1, Compositions, And Methods Of Use | GALR1, GALR3, GALR2 | ALDH1A1 4001/4885KDM4E 2832/4885HPGD 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.